CNS/Neurology
Search text
Donald William Landry MD, Ph.D.
3 results
(0.02 seconds)
This technology includes two chemical compounds that are phosphodiesterase type 5 (PDE5) inhibitors with a benzonaphthyridine derivative chemical scaffold that has not previously been used to treat Alzheimer’s disease or other conditions involving phosphodiesterase PDE5 function.
This technology is a tool to identify compounds that block the activity of TIA1, an RNA-binding protein that regulates stress granule formation and the generation of pathological forms of tau protein, and is implicated in a range of neurodegenerative diseases.
This technology is a group of lead compounds that effectively prevent TIA1 multimerization and subsequent aggregation of tau protein for treatment of neurodegenerative diseases.